INTRODUCTION
Spontaneous autoantibodies directed against cell surface receptors for polypeptide hormones and neurotransmitters are well-known mediators of autoimmune illness (1) . Passive transfer of acetylcholine receptor autoantibodies obtained from patients with myasthenia gravis recreates the disease in experimental animals (2) . In Graves' disease, passive transfer of thyroid-stimulating autoantibody to rodents (3) produces a delayed and prolonged elevation of thyroxine in the blood (the long-acting thyroid stimulator, [LATS]' effect).
In patients with autoantibodies to the insulin receptor (Anti-R), three distinct metabolic states are seen:
(a) most typically, severe fasting hyperglycemia is associated with extreme resistance to endogenous and exogenous insulin; (b) fasting hyperglycemia is followed by spontaneous fasting hypoglycemia, or on occasion, there is an alternating pattern of hypoglycemia and hyperglycemia; (c) less commonly, hypoglycemia occurs as the sole metabolic manifestation of the disease. In vitro, autoantibodies mimic most, if not all, of insulin's effects and competitively inhibit binding of insulin to its receptor (4 Plasma obtained from four patients who spontaneously developed Anti-R was studied. These patients are referred to as B-1, B-6, B-10, and B-12. Their clinical features may be found in Table I and in previous reports (5) (6) (7) (8) (9) (10) . Patients B-6 and B-10 had received insulin previously, but only patient B-10 had detectable anti-insulin antibodies. Control plasma without Anti-R was obtained and processed in the same manner as the Anti-R plasma. Control subjects included normal volunteers with normal glucose tolerance and a patient with lupus erythematosus under treatment with prednisone and plasmapheresis.
Immunoglobulin extraction. Freeze-thawed plasma samples of up to 500 ml were diluted with phosphate-buffered saline, pH 8.0 (PBS). The sample was then applied to a 5 X 6-cm staphylococcal protein A-Sepharose column (Pharmacia, Uppsala, Sweden) equilibrated with PBS. Samples were recycled over this column two or three times, washed with _10 column vol of PBS, and eluted with 0.1 M citratebuffered saline, pH 3.0 (11) . The acid eluate was concentrated using an ultrafiltration membrane (PM-30, Amicon Corp., Scientific Sys. Div., Danvers, MA) and neutralized with sodium hydroxide. The protein A-Sepharose IgG affinity columns described were capable of absorbing 25 g of IgG, but yielded only -50% of the IgG contained in the samples applied. Further losses were sustained in subsequent procedures, which limited the quantities of IgG available for testing in vivo. To reduce the potential for plasma component carry-over from one IgG preparation to another, a separate protein A-Sepharose column was used to extract IgG from plasma of patient B-10. The content of IgM and IgA in the concentrated eluates from the protein A columns was <1% of the total IgG extracted.
Unlike plasma from patients B-1, B-6, and B-12, which was limited in quantity, plasma from patient B-10 was most abundant for study, but was known to contain a low titer of anti-insulin antibodies (1:10) as well as elevated levels of insulin. Partial removal of these antibodies was achieved by 33% ammonium sulfate precipitation of B-10 plasma followed by affinity chromatography using Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) to which porcine insulin was coupled. The flow-through from this column was then chromatographed on protein A-Sepharose as described.
To be certain that neither insulin bound to anti-insulin antibodies or free insulin was present in significant amounts after protein A-Sepharose chromatography, two additional purification steps were taken. First, the Anti-R IgG fraction was applied to a Sephadex G-50 column equilibrated in 0.05 M ammonium carbonate (pH 8.0) and eluted with the same buffer. At this stage, <10 ng of free insulin/ml of concentrated sample was detected. To dissociate any insulin potentially bound to anti-insulin antibody, a similar gel filtration was carried out in 1.0 M acetic acid (pH 3.0) (12) . The void volumes of the alkaline and acid columns were then concentrated for subsequent assay.
Analysis of immunoglobulin preparations. Protein concentration of the immunoglobulin preparations was estimated by adsorption at 280 nm. Human IgG concentrations were estimated by radial immunodiffusion (13) . Total and free immunoreactive insulin concentrations were determined using standard radioimmunoassay techniques (14, 15) . Anti-insulin receptor antibody titers were determined by their inhibition of '25I-insulin binding to cultured lymphocytes (16) . Glucose oxidation and insulin binding to rat adipocytes in the presence of B-10 IgG was studied as described (17) .
Collection of venous blood specimens from unrestrained rats. Chronic venous access in the unrestrained rat (SpragueDawley rats, Charles River Breeding Laboratories, Wilmington, MA) was achieved using aseptic surgical techniques as described in reference 18. Two specially constructed cages each housing a single rat were used in these studies. Immunoglobulin administration. The partially purified immunoglobulins were injected into a total of nine rats (eight female and one male) by two basic protocols. The first protocol involved an acutely administred, single intraperitoneal injection given after 15±3 h of fasting. If more than one injection was given to an individual rat, a recovery period of a week or more was allowed during which it was established that plasma glucose values had returned to control levels. This single injection protocol was followed for the data presented in Figs. 3 Animal evaluation. The rats were weighed two or three times per week. All animals increased in weight independently of the sequence or nature of the intraperitoneal injections they received. In some animals, food intake was measured and was found to fluctuate with changes in body weight. During fasting periods, the activity and appearance of the animals was carefully observed. If the animal became difficult to arouse or if matted facial hair secondary to protracted periods of hypoglycemia was noted, the fasting period was terminated. Provision of food pellets alone was adequate for the recovery of most hypoglycemic animals, but an intravenous infusion of concentrated dextrose (D20-50%) was required in some instances.
RESULTS
In vitro effects of Anti-R IgG in isolated adipose cells. It has been demonstrated that Anti-R plasma has effects similar to those of insulin in isolated adipocytes and, in addition, competitively inhibits insulin binding (17) . When the partially purified IgG from patient B-10 was incubated with isolated adipocytes, glucose oxidation was stimulated in a dose-dependent fashion (Fig. 1) . B-10 IgG also inhibited the binding of '251-insulin to these cells in a similar, dose-dependent manner. At each concentration of B-10 and B-12 (9) IgG, glucose oxidation was stimulated to a greater extent than it inhibited 1251-insulin binding. These effects of Anti-R are typical of isulin's action under similar conditions (9) .
Passive transfer of IgG to the rat. After recuperation from surgery, for periods usually .4 d, blood specimens were drawn from unrestrained, cannulated rats. The plasma glucose of both fed and fasted rats was monitored with and without control injections. The plasma glucose did not fall below 75 mg/dl (n = 83) during a 40-h fast in these control experiments. Occasionally, an acute rise in glucose occurred within When Anti-R IgG was injected intraperitoneally into fasted rats, there was a progressive fall in the plasma glucose concentration within a 2-4-h period. The hypoglycemic effect persisted for 8-24 h after injection and, in some instances, the animals required food or glucose infusion to prevent hypoglycemic coma or death (Fig. 3 A) . The effect was dose-dependent in that IgG obtained from patient B-10, after repeated plasmapheresis treatments (Fig. 3 B) , showed the same qualitative, prolonged hypoglycemic effect as before (Fig. 3 A) , but was quantitatively less potent.
Passive transfer of IgG from hypoglycemic and hyperglycemic Anti-R patients. Based on the gel filtration studies at acid pH of B-10 IgG, we were confident that its hypoglycemic effect in the rat did not result from insulin slowly released from anti-insulin antibody (Fig. 3) . However, we wished to test plasma from other patients in whom anti-insulin antibodies were not present (Table I) . Of special note is the effect of Anti-R IgG from patient B-12 (Fig. 4) . This patient had never been treated with insulin, had no demonstrable anti-insulin antibodies, and was hypoinsulinemic. The sole clinical manifestation of her anti-R was spontaneous, severe fasting hypoglycemia (9) . The Anti-R IgG from patient B-12, tested on three occasions, produced the same persistent hypoglycemic effect in the rat as IgG from patient B-10 (Fig. 4) . The Anti-R IgG from patient B-1, tested on only one occasion, produced a less pronounced, but still significant hypoglycemic response (Fig. 4) .
The hypoglycemic effect of Anti-R IgG is distinct from that of insulin. The effects of varying doses of regular crystalline insulin and B-10 IgG on the plasma glucose of the fasted rat were compared in Fig. 5 . When insulin was administered intraperitoneally to the fasted rat at a dose of 50 ng/kg body wt, there was no effect on plasma glucose. With an insulin dose of 100 ng/kg body wt, a typical, rapidly induced hypoglycemic phase was followed by recovery. With 350 ng insulin/kg body wt, the resultant rapid and continuous fall in plasma glucose prompted the administration of intravenous glucose to prevent death. By contrast, a more slowly induced, persistent hypoglycemic effect occurred with injection of B-10 IgG obtained from the void volume of a Sephadex G-50 column (pH 8.0).
Hyperglycemic effect of Anti-R IgG. While partially purified Anti-R has insulin-like effects when exposed to cultured cells for short intervals, longer exposure to Anti-R desensitizes cells to the effects of both Anti-R and insulin in vitro (19, 20) . Therefore, we wished to determine the effect of larger concentrations of Anti-R IgG given repeatedly over longer periods of time on the plasma glucose of our in vivo rat model.
As shown in Fig. 6 , injections of Anti-R IgG were begun after a 15-h fast and were accompanied by a decrease in plasma glucose concentration. Following this, the rat was fed and injections were continued. Note that with feeding and continued injections hyperglycemia ensued and was maintained for 5 d (Fig.  6) . At this point, with fasting and an injection of Anti-R B-6 IgG, another decline in plasma glucose was induced.
In a series of injections carried out in different animals, hypoglycemia was typically observed in the fasted state after the acute administration of Anti-R IgG while hyperglycemia was typically observed in the fed state ( Fig. 7 and Table II) . Thus, in addition to the acute administration of the Anti-R IgG, the fasted state is a prerequisite for the induction of hypoglycemia. Neither the presence of the antibody nor fasting per se independently induced hypoglycemia in Anti-R injected rats. Similarly, the repeated administration of the Anti-R IgG to the fed animal is a prerequisite to the induction of hyperglycemia. 
DISCUSSION
The major finding in this study is that passive transfer to rats of an IgG fraction from patients with autoantibodies to the insulin receptor produces a prolonged hypoglycemic response. The IgG preparation from patient B-10 was analyzed to show that neither its content of trace quantities of free insulin nor insulin bound to anti-insulin antibodies caused hypoglycemia in the Table I ) on the fasting plasma glucose of rats. B- The present study is the first report of the effects of Anti-R IgG passively transferred to experimental animals and provides further information on the pathogenesis of the metabolic aspects of the humoral disease associated with Anti-R. Previous in vitro studies have demonstrated that Anti-R plasma mimics most of insulin's biologic effects (4) . The results obtained in this FIGURE 7 Plasma glucose of rats during fasting and feeding after injections with Anti-R IgG or control IgG from a lupus patient. These are pooled data derived from individual experiments of a design similar to that shown in Fig. 6 Table II Table II . The levels of statistical significance shown were derived using the t test. study are a direct demonstration that this same type of response occurs in vivo.
Mechanism of Anti-R-induced hypoglycemia. Anti-R IgG when injected intraperitoneally into the fasted rat typically produces a progressively more intense hypoglycemic response requiring several hours to reach a nadir. Once the nadir of the response is reached, hypoglycemia, induced by a single pulse injection, may persist for several hours. In vitro, binding of the Anti-R IgG and the resultant biologic response is of rapid onset and similar to insulin's effect. The slow onset of the in vivo response most likely results from delayed transport of the Anti-R IgG from the peritoneal cavity and intravascular space to its sites of action. The prolongation of the response would be anticipated since the dissociation rate of the Anti-R IgG from the cell is slow. To induce an in vitro response, the Anti-R IgG must be bivalent with optimal activation of the cell occurring at physiologic temperatures in a concentration-dependent fashion (16) . All of these conditions are present in vivo in the rat. Thus, the major initial effect of the Anti-R IgG in vivo is to act as an insulin agonist.
Mechanism of the hyperglycemic response to Anti-R. When Anti-R IgG is given repeatedly in large doses Passive Transfer Anti-Insulin Receptor Antibodies Each experiment was performed in an individual rat after a control period. Experiments 4 and 6 were performed in the same rat, with an intervening 3-wk control period. Experiments 5 and 6 are shown in Fig. 6 . e B-10 IgG after insulin affinity and protein A-Sepharose chromatography (see Fig. 3 A) .
I B-10 IgG-eluted and concentrated directly from the protein A-Sepharose column. § B-6 IgG prepared as in e. 1 (20) . In addition, however, desensitization requires a latency period as well as a particular milieu during in vitro incubation.
For desensitization to occur, the incubation medium must include glucose or pyruvate, but 2-deoxyglucose, glucosamine, or mannose may substitute as well (20) .
Whether these small molecules serve as cofactors or act in some other way is unknown.
In patients, the most typical clinical feature of the disease associated with Anti-R IgG is hyperglycemia and insulin resistance. All these patients demonstrate the characteristic low affinity receptor defect on their circulating blood cells (7) . Thus, one mechanism whereby the Anti-R IgG may cause insulin resistance is by occupancy of the insulin receptor and competitive inhibition of insulin binding. Such a phenomenon has been demonstrated in vitro and is operative analogous to other circumstances in which the number or affinity of hormone receptors is reduced. In addition, it seems reasonable to speculate that hyperglycemia in the patient and in the rat with Anti-R IgG results, in part, from a desensitization process analogous to that seen in the tissue culture system.
Other potential mechanisms associated with Anti-R-related diseases. A variety of different pathogenic mechanisms have been demonstrated to mediate other anti-receptor antibody effects. In patients with myasthenia gravis, antibodies to the acetylcholine receptor are known to decrease the number of available receptors both by increasing their degradation rate and blocking their binding to neurotransmitter (22) . This same type of mechanism may be relevant to the antiinsulin receptor IgG, but this has not been demonstrated at the present time. In patients with Graves' disease, heterogenous subpopulations of antibodies that either stimulate or inhibit the TSH receptor may be isolated with monoclonal techniques. These antibodies appear to interact with different subunits of the TSH receptor to mediate their different effects (23) . Monoclonal antibodies to the IM-9 insulin receptor have been produced in rodents (24) . However, these antibodies do not mimic the action of insulin in vitro even though they block insulin binding and inhibit insulin action. It is possible that polyclonal Anti-R IgG circulating in patients may be comprised of two differently functioning antibodies, but this has not been demonstrated. By analogy with circulating antibodies found in Graves' disease patients (24) The simplest formulation is to suggest that hypoglycemia results from the direct insulinlike agonistic effect of the Anti-R IgG. These insulinlike effects seen in freshly isolated and cultured cells, as well as in vivo in the rat, and in hypoglycemic Anti-R patients are all consistent with this type of mechanism.
In patients, however, the most typical clinical picture is hyperglycemia and insulin resistance. Thus, prolonged exposure of the Anti-R IgG to cultured cells, or to rats in vivo, leads to a desensitization effect in vitro, and hyperglycemia in vivo. If we speculate that desensitization occurs in vivo, then the combination of this effect with competitive inhibition of insulin binding could explain the insulin-resistant hyperglycemic state. Another important variable in both the rat and the patient is food intake. Caloric restriction is necessary to demonstrate hypoglycemia in the rat and feeding is necessary for the hyperglycemic response. Even when Anti-R patients are extremely resistant to insulin, a 24-h fast may bring their blood glucose values down to normal. However, resolution of hyperglycemia by fasting these patients is unaccompanied by any change in insulin binding (7) .
The fact that Anti-R IgG from hypoglycemic patient B-12 and hyperglycemic patient B-10 have essentially the same effects on isolated fat cells in vitro (compare our Fig. 1 with Fig. 2 of reference 9 ) and the same acute response in vivo in the rat (see Fig. 4 ) suggests that the net metabolic response is not determined by heterogeneity of the Anti-R IgG, but is determined by the host tissue response. In instances where desensitization does not occur, then hypoglycemia prevails. In the more typical situation where desensitization predominates, an insulin-resistant hyperglycemic state appears. The factors that mediate this presumably postreceptor desensitization state or prevent it from occurring are unknown at present. The factors involved, however, are likely to be closely related to the mechanisms by which the insulin receptor transduces its biological signal.
